Standard BioTools Debt to Equity Ratio 2010-2024 | LAB
Current and historical debt to equity ratio values for Standard BioTools (LAB) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Standard BioTools debt/equity for the three months ending June 30, 2024 was 0.00.
| Standard BioTools Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.20B |
$0.51B |
0.39 |
| 2024-03-31 |
$0.20B |
$0.58B |
0.35 |
| 2023-12-31 |
$0.16B |
$0.16B |
0.98 |
| 2023-09-30 |
$0.16B |
$0.18B |
0.89 |
| 2023-06-30 |
$0.16B |
$0.20B |
0.80 |
| 2023-03-31 |
$0.16B |
$0.21B |
0.74 |
| 2022-12-31 |
$0.16B |
$0.23B |
0.70 |
| 2022-09-30 |
$0.17B |
$0.25B |
0.67 |
| 2022-06-30 |
$0.17B |
$0.27B |
0.61 |
| 2022-03-31 |
$0.25B |
$0.02B |
11.30 |
| 2021-12-31 |
$0.18B |
$0.10B |
1.91 |
| 2021-09-30 |
$0.18B |
$0.10B |
1.84 |
| 2021-06-30 |
$0.18B |
$0.11B |
1.64 |
| 2021-03-31 |
$0.18B |
$0.12B |
1.48 |
| 2020-12-31 |
$0.19B |
$0.14B |
1.34 |
| 2020-09-30 |
$0.17B |
$0.15B |
1.13 |
| 2020-06-30 |
$0.15B |
$0.13B |
1.13 |
| 2020-03-31 |
$0.15B |
$0.14B |
1.05 |
| 2019-12-31 |
$0.11B |
$0.15B |
0.72 |
| 2019-09-30 |
$0.11B |
$0.16B |
0.66 |
| 2019-06-30 |
$0.11B |
$0.17B |
0.64 |
| 2019-03-31 |
$0.11B |
$0.18B |
0.60 |
| 2018-12-31 |
$0.23B |
$0.07B |
3.21 |
| 2018-09-30 |
$0.23B |
$0.02B |
10.26 |
| 2018-06-30 |
$0.22B |
$0.04B |
6.44 |
| 2018-03-31 |
$0.22B |
$0.05B |
4.55 |
| 2017-12-31 |
$0.26B |
$0.03B |
8.29 |
| 2017-09-30 |
$0.25B |
$0.04B |
6.47 |
| 2017-06-30 |
$0.26B |
$0.02B |
10.64 |
| 2017-03-31 |
$0.25B |
$0.04B |
6.60 |
| 2016-12-31 |
$0.25B |
$0.05B |
4.76 |
| 2016-09-30 |
$0.25B |
$0.07B |
3.71 |
| 2016-06-30 |
$0.26B |
$0.08B |
3.06 |
| 2016-03-31 |
$0.26B |
$0.10B |
2.58 |
| 2015-12-31 |
$0.26B |
$0.12B |
2.22 |
| 2015-09-30 |
$0.25B |
$0.12B |
2.05 |
| 2015-06-30 |
$0.26B |
$0.13B |
1.92 |
| 2015-03-31 |
$0.25B |
$0.14B |
1.77 |
| 2014-12-31 |
$0.26B |
$0.15B |
1.71 |
| 2014-09-30 |
$0.26B |
$0.16B |
1.66 |
| 2014-06-30 |
$0.26B |
$0.16B |
1.58 |
| 2014-03-31 |
$0.26B |
$0.17B |
1.54 |
| 2013-12-31 |
$0.02B |
$0.10B |
0.21 |
| 2013-09-30 |
$0.02B |
$0.10B |
0.18 |
| 2013-06-30 |
$0.01B |
$0.10B |
0.14 |
| 2013-03-31 |
$0.01B |
$0.10B |
0.13 |
| 2012-12-31 |
$0.01B |
$0.10B |
0.13 |
| 2012-09-30 |
$0.01B |
$0.10B |
0.14 |
| 2012-06-30 |
$0.02B |
$0.05B |
0.33 |
| 2012-03-31 |
$0.02B |
$0.05B |
0.36 |
| 2011-12-31 |
$0.02B |
$0.06B |
0.39 |
| 2011-09-30 |
$0.02B |
$0.06B |
0.40 |
| 2011-06-30 |
$0.02B |
$0.06B |
0.38 |
| 2011-03-31 |
$0.03B |
$0.07B |
0.38 |
| 2010-12-31 |
$0.21B |
$-0.19B |
-1.13 |
| 2010-09-30 |
$0.02B |
$-0.00B |
-12.97 |
| 2010-06-30 |
$0.00B |
|
0.00 |
| 2010-03-31 |
$0.00B |
|
0.00 |
| 2009-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Information Systems |
$0.763B |
$0.106B |
|
Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif.
|
